ELISA reagent coverage evaluation by affinity purification tandem mass spectrometry

Host cell proteins (HCPs) must be adequately removed from recombinant therapeutics by downstream processing to ensure patient safety, product quality, and regulatory compliance. HCP process clearance is typically monitored by enzyme-linked immunosorbent assay (ELISA) using a polyclonal reagent. Rece...

Descripción completa

Detalles Bibliográficos
Autores principales: Henry, Scott M., Sutlief, Elissa, Salas-Solano, Oscar, Valliere-Douglass, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2017
Materias:
Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5627587/
https://www.ncbi.nlm.nih.gov/pubmed/28708446
http://dx.doi.org/10.1080/19420862.2017.1349586

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5627587/
https://www.ncbi.nlm.nih.gov/pubmed/28708446
http://dx.doi.org/10.1080/19420862.2017.1349586

Ejemplares similares